ArticleMolecular psychiatry2011
Evidence for disease and antipsychotic medication effects in post-mortem brain from schizophrenia patients.
Article in Molecular psychiatry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 87 citations in OpenAlex.
- Article
- Pharmaco-Multiomics: A New Frontier in Precision Psychiatry.International journal of molecular sciences · 2025Review
- Vitamin C Alleviates the Negative Effects of Heat Stress on Reproductive Processes by Regulating Amino Acid Metabolism in Granulosa Cells.Antioxidants (Basel, Switzerland) · 2024Article
- Proteome analysis of the prefrontal cortex and the application of machine learning models for the identification of potential biomarkers related to suicide.Frontiers in psychiatry · 2024Article
- Acute IL-6 exposure triggers canonical IL6Ra signaling in hiPSC microglia, but not neural progenitor cells.Brain, behavior, and immunity · 2023Article
- Antipsychotic drug use complicates assessment of gene expression changes associated with schizophrenia.Translational psychiatry · 2023Article
- Aberrant glycosylation in schizophrenia: a review of 25 years of post-mortem brain studies.Molecular psychiatry · 2020Review
- Metabolomics in Psychiatric Disorders: What We Learn from Animal Models.Metabolites · 2020Review
- Transcriptomic immaturity inducible by neural hyperexcitation is shared by multiple neuropsychiatric disorders.Communications biology · 2019Article
- Dysbindin-1 contributes to prefrontal cortical dendritic arbor pathology in schizophrenia.Schizophrenia research · 2018Article
- Creation of a myosin Va-TAP-tagged mouse and identification of potential myosin Va-interacting proteins in the cerebellum.Cytoskeleton (Hoboken, N.J.) · 2018Article
- Metabolomic Analysis in Brain Research: Opportunities and Challenges.Frontiers in physiology · 2016Article
- Omics-Based Biomarkers: Application of Metabolomics in Neuropsychiatric Disorders.The international journal of neuropsychopharmacology · 2015Review
- Metabolic Profiling and Phenotyping of Central Nervous System Diseases: Metabolites Bring Insights into Brain Dysfunctions.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2015Review
- Disturbed macro-connectivity in schizophrenia linked to oligodendrocyte dysfunction: from structural findings to molecules.NPJ schizophrenia · 2015Review
- MK-801 treatment affects glycolysis in oligodendrocytes more than in astrocytes and neuronal cells: insights for schizophrenia.Frontiers in cellular neuroscience · 2015Article
- Transcriptome profiling of human hippocampus dentate gyrus granule cells in mental illness.Translational psychiatry · 2014Article
- Antipsychotics activate mTORC1-dependent translation to enhance neuronal morphological complexity.Science signaling · 2014Article
- A combined metabonomic and proteomic approach identifies frontal cortex changes in a chronic phencyclidine rat model in relation to human schizophrenia brain pathology.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2013Article
- Recent advances in quantitative neuroproteomics.Methods (San Diego, Calif.) · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extensive research has been conducted on post-mortem brain tissue in schizophrenia (SCZ), particularly the dorsolateral prefrontal cortex (DLPFC). However, to what extent the reported changes are due to the disorder itself, and which are the cumulative effects of lifetime medication remains to be determined. In this study, we employed label-free liquid chromatography-mass spectrometry-based proteomic and proton nuclear magnetic resonance-based metabonomic profiling approaches to investigate DLPFC tissue from two cohorts of SCZ patients grouped according to their lifetime antipsychotic dose, together with tissue from bipolar disorder (BPD) subjects, and normal controls (n=10 per group). Both techniques showed profound changes in tissue from low-cumulative-medication SCZ subjects, but few changes in tissue from medium-cumulative-medication subjects. Protein expression changes were validated by Western blot and investigated further in a third group of subjects who were subjected to high-cumulative-medication over the course of their lifetime. Furthermore, key protein expression and metabolite level changes correlated significantly with lifetime antipsychotic dose. This suggests that the detected changes are present before antipsychotic therapy and, moreover, may be normalized with treatment. Overall, our analyses revealed novel protein and metabolite changes in low-cumulative-medication subjects associated with synaptogenesis, neuritic dynamics, presynaptic vesicle cycling, amino acid and glutamine metabolism, and energy buffering systems. Most of these markers were altered specifically in SCZ as determined by analysis of the same brain region from BPD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.